PKP-010 Levetiracetam clinical pharmacokinetics in elderly patients with epilepsy

Background Levetiracetam (LEV) is increasingly used in the elderly due to a favourable pharmacokinetic profile, good tolerability and no significant drug–drug interactions. LEV is renally excreted, and its clearance is expected to decrease during old age because of the physiological reduction in glomerular filtration rate. Purpose To compare apparent steady state oral clearance of levetiracetam (LEV CL/F) in elderly versus non-elderly patients with epilepsy. Material and methods This was a retrospective study from 2009 to 2013 in 380 adult patients with epilepsy treated with LEV. Inclusion criteria: age ≥16 years; treatment with LEV for at least 1 month; and venous blood sampling before the first morning dose of LEV. Variables collected were dose, serum concentration, age, sex, body weight and anticonvulsant comedications prescribed. They were obtained from the therapeutic drug monitoring register and the medical records. Patients were grouped according to age: group A (16–30 years, n=93), group B (31–50 years, n=131), group C (51–65 years, n=90) and group D (u003e65 years, n=66). In group D, 15.15% of patients had impaired renal function (creatinine clearance Results Mean basal LEV serum concentrations (µg/mL) significantly increased with age. We compared group A (13.32±4.54) versus B (14.01±6.43) (NS); group A vs C (17.54±5.45) (p Conclusion LEV CL/F significantly declined with ageing, with a reduction in median values ranging from 20% in patients aged 50–65 years to 35% in those over 65 years compared with non-elderly patients. To achieve a given serum drug concentration, LEV dose should be reduced by around 30% in elderly patients compared with younger subjects. No conflict of interest